Hair Dyes and Cancer Risk

Although some studies have linked the personal use of hair dyes with increased risks of certain cancers of the blood and bone marrow, such as non-Hodgkin lymphoma (NHL) and leukemia, other studies have not shown such links. Studies of breast and bladder cancer have also produced conflicting results. Relatively few studies have been published about the association of hair dye use with the risk of other cancers. Based on its review of the evidence, the IARC Working Group concluded that personal use of hair dyes is “not classifiable as to its carcinogenicity to humans”

Drug Reduces Cancer Treatment-Related Joint Pain 

After undergoing treatment for early-stage breast cancer, many postmenopausal women take drugs known as aromatase inhibitors to reduce the risk of the cancer returning. These drugs, however, can cause significant pain in women’s joints and muscles. The clinical trialExit Disclaimer showed that duloxetine (Cymbalta®), which is approved to treat depression and anxiety as well as fibromyalgia and nerve pain caused by diabetes, provided some relief from pain associated with aromatase inhibitors.

5 Reasons Cancer and Sugar are Best Friends

Although we should avoid sugar, artificial sugar substitutes containing aspartame, saccharin or sucralose have been shown to contribute to bladder cancer, lymphoma and leukemia, according to the National Institute of Environmental Health Sciences. Good sugar substitutes are stevia (an all-natural herb from South America), barley malt, rice syrup, and palm sugar. Even high-glycemic sweeteners like Sucanat, evaporated cane juice, molasses, honey and pure maple syrup are nutritionally superior to refined table sugar or HFCS, and you can avoid sugar spiking if you consume them in the presence of high fiber foods like ground flaxseeds.

Signs of breast cancer explained, using lemons 

Is that a lump I can feel? Should I be worried about the dimpled skin there? What exactly am I feeling for? Those were the concerns of Corrine Beaumont, a young designer, who created the ‘Know Your Lemons’ campaign, which has been shared more than 32,000 times on Facebook in the past few days.

Breast Cancer ‘Chemo Brain’ Reported For Months After Treatment, Study Says

“Our study, from one of the largest nationwide studies to date, shows that cancer-related cognitive problems are a substantial and pervasive issue for many women with breast cancer,” Janelsins-Benton, an assistant professor of surgery, said in a press release. “We are currently assessing these data in the context of objective cognitive measures and to understand the role of possible biologic mechanisms that may confer risk to cognitive problems in patients.”

Minimally Invasive Breast Cancer Cryotherapy Largely Ignored in U.S., Says Advocate and 13-Year Survivor 

Laura Ross-Paul of Portland, Oregon, calls herself a “patient pioneer,” as one of the first women in the world to receive cryoablation as the primary treatment for her multi-focused breast cancer 13 years ago.“The beauty of cryoablation,” Ross-Paul said, “is that it is breast conserving — I was able to avoid a mastectomy,” its low morbidity — “I never needed more than a Tylenol,” and its inexpensive cost compared to surgery. Ross-Paul says another major benefit of cryoablation is that in about half of all cases, “cryoablation naturally stimulates the body’s immune system to develop an immunity to the cancer as it eats up the now-dead tumors.”

Metaplastic-breast-cancer Treatment Looks Promising

In just under four years, researchers have identified the gene involved in the development of metaplastic breast cancer — the most aggressive type of triple-negative breast cancer — and advanced a potential treatment for the disease to clinical trials. “The results showed elimination of the cancer in nearly all of the mice when combined with standard chemotherapy,” said Chang, who is also a professor of medicine at Weill Cornell Medicine. “Our goal is to turn metaplastic breast cancer from a debilitating disease into a chronic illness.

Breast-cancer Vaccine Using Dendritic Cells Can Cause Regression

A new cancer vaccine that uses a patient’s own immune-regulating dendritic cells to target the HER2 protein can activate the immune system and cause regression of early-stage HER2-positive breast cancer, according to a study. The therapy is particularly effective in patients with a non-invasive form of the disease called ductal carcinoma in situ (DCIS), as compared with patients with an early-stage invasive disease, researchers said.

Enzymes’ Role in Breast Cancers That Are Estrogen Receptor-positive Identified

Researchers have identified two new factors that may help to determine whether a patient with estrogen receptor-positive breast cancer will respond to treatment. In addition to preventing the estrogen receptor from being degraded — and impairing drugs that target it from combating the cancer — a lack of the enzymes LATS1 and LATS2 makes cancer development much more likely, according to “The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα.” The study was published in the journal Nature.

The 7 Most Toxic Ingredients In Everyday Cosmetic Products

The FDA and Congress should develop tougher requirements for proving cosmetic chemicals are safe before coming to market. All too often, products are on the market for years before scientists catch up with possible hazards in their formulations. Once hazards are suspected, the FDA moves at a snail’s pace in regulating potentially harmful ingredients. Responsible manufacturers can voluntarily remove these ingredients and we hope they will. Ultimately, it’s up to consumers to read labels, vote with their pocketbooks and force the market to change for the better.

Study finds substantial rate of contralateral prophylactic mastectomy when procedure not indicated 

Adapted Media Release
Breast Cancer
Surgery
Study finds substantial rate of contralateral prophylactic mastectomy when procedure not indicated

Published: Monday 2 January 2017
email11SHARE
In a survey of women who underwent treatment for early-stage breast cancer in one breast, contralateral prophylactic mastectomy (CPM; both breasts are surgically removed, the breast that contains cancer and the healthy breast) use was substantial among patients without clinical indications but was low when patients reported that their surgeon recommended against it, according to a study published online by JAMA Surgery. Many patients considered CPM, but knowledge about the procedure was low and discussions with surgeons appeared to be incomplete.